Opko Health Rises As Modex Starts Early Trial Of Covid: 19 prevention antibody

OPKO Health

08/04/2026 13:50

** Shares of biotech firm OPKO Health OPK.O rise 1.7% to $1.19 premarket

** Co says its unit ModeX Therapeutics begins dosing volunteers in an early-stage study

** ModeX’s experimental antibody MDX2301 is being tested to prevent COVID-19, an infectious respiratory disease that can be severe in older adults and people with long-term illnesses, co says

** Says early-stage trial will enrol about 80 healthy adults and high‑risk people to test safety, how the drug behaves in the body and its ability to block the virus

** Adds MDX2301 is designed to block all known variants and is given by vein or muscle injection; it is not yet approved

** Says study is funded by the U.S. government’s BARDA and could support similar approaches for other viruses such as influenza

** As of last close, stock down ~7% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))